3e17c945-a810-4d82-af11-93debdee3f21
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 311f1988-e21e-4130-b944-2a34d7d46d28 | — | — | 0.849 |
| 2 | TCGA-AR-A252-01A-11R-A169-07 | — | A | 0.848 |
| 3 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.839 |
| 4 | DRR168557 | — | — | 0.829 |
| 5 | 2833b2f4-e943-4570-96c2-a42c127cd1fa | — | — | 0.827 |
| 6 | TCGA-OR-A5JV-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.824 |
| 7 | TCGA-AC-A2FB-01A-11R-A17B-07 | — | A | 0.819 |
| 8 | TCGA-CN-5369-01A-01R-1436-07 | — | — | 0.816 |
| 9 | SRR8518215 | — | D | 0.815 |
| 10 | 5566453e-df41-4aab-8dd0-825efbece954 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |